Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 9, 2026International Journal of Innovative Technologies in Social ScienceOpen Access

Advances in genetics, imaging, and targeted therapies enhance management of hypertrophic cardiomyopathy, leading to personalized treatment and lower sudden death risk.

View Full Paper
Ask AI
Bookmark
Share

Key result

Advances in genetics, imaging, and targeted therapies enhance management of hypertrophic cardiomyopathy, leading to personalized treatment and lower sudden death risk.

Authors

AWAnna WoźniakAGAleksandra GrygorowiczKBKlaudia Baran

Discussion

Loading...

Member takes

Overview

This review examines advances in diagnosis and treatment of hypertrophic cardiomyopathy, suggesting improved patient outcomes and personalization of care.

Key Points

  • The aim is to explore recent advancements in diagnostics and treatments for hypertrophic cardiomyopathy and their implications for personalized patient care.
  • Review of pathophysiology, genetics, and clinical features of hypertrophic cardiomyopathy.
  • Examination of recent diagnostic technologies like echocardiography and cardiac MRI.
  • Analysis of genetic testing and identification of sarcomere mutations.
  • Discussion of emerging therapies, including myosin inhibitors and gene therapy.
  • Overview of patient management strategies and digital monitoring tools.
  • Echocardiography and cardiac MRI effectively assess left ventricular hypertrophy and fibrosis.
  • Genetic analysis uncovers sarcomere gene mutations linked to HCM.
  • Cardiac myosin inhibitors enhance symptom relief and quality of life when combined with conventional therapies.
  • Surgical interventions like myectomy and alcohol septal ablation reduce symptoms and sudden death risk.
  • Digital tools facilitate personalized treatment approaches in managing HCM.

Study Design

Type

null

PICO

P
Population
Hypertrophic cardiomyopathy
I
Intervention / Comparator
mavacamten vs conventional therapy (null)
O
Primary Outcome
Reduction in left ventricular outflow tract gradients and improvement in quality of life — null (null), p=null

Main Result

Effect estimate: null (95% CI null)

p-value: p=null

Limitations

  • Limited long-term efficacy data on new therapies.
  • Incomplete understanding of phenotypic heterogeneity.

Cite This Study

Woźniak et al. (2025) conducted a null in Hypertrophic cardiomyopathy. mavacamten vs. conventional therapy was evaluated on Reduction in left ventricular outflow tract gradients and improvement in quality of life (null, 95% CI null, p=null). Advances in genetics, imaging, and targeted therapies enhance management of hypertrophic cardiomyopathy, leading to personalized treatment and lower sudden death risk.

synapsesocial.com/papers/69609561f6dae357db7c13d0https://doi.org/10.31435/ijitss.4(48).2025.4716
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Current and emerging medical and surgical therapy in hypertrophic cardiomyopathy2025
  2. 2Hypertrophic Cardiomyopathy: Current Perspectives2025
  3. 3Targeted Therapies in Hypertrophic Cardiomyopathy: A Practical Review of Evidence, Implementation, and Innovation2026
  4. 4Genetic insights into hypertrophic cardiomyopathy: pathogenesis, diagnosis, and therapeutic implications2025 · 9 citations
  5. 5Expanding the Role of Myosin Inhibition in Hypertrophic Cardiomyopathy — A Tale of Two Conditions2025 · 2 citations